Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp (NASDAQ: KTTA) is a clinical-stage biotechnology company advancing novel therapies for central nervous system disorders and genetic conditions. This dedicated news hub provides investors and industry observers with timely updates on the company's scientific progress, regulatory milestones, and strategic initiatives.
Our curated collection offers comprehensive tracking of KTTA's developments including clinical trial updates for its lead candidate PAS-004, research collaborations, and advancements in treating conditions like Neurofibromatosis Type 1 and ALS. The content is organized to help stakeholders efficiently monitor the company's progress in neuroscience innovation and drug development.
Key updates cover regulatory filings, partnership announcements, peer-reviewed research publications, and clinical trial results. All content maintains strict editorial standards to ensure accuracy and relevance for both professional investors and those new to biotech equities.
Bookmark this page for centralized access to verified information about Pasithea's therapeutic pipeline, including its work on MEK inhibitors and translational medicine approaches. Check back regularly for essential updates that could impact long-term research trajectories and market positioning.
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a clinical-stage biotech company, will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company is developing PAS-004, a next-generation macrocyclic MEK inhibitor for treating neurofibromatosis type 1 (NF1) and other cancer indications.
Key points:
- Presentation available online from 7:00 a.m. ET on September 9th, 2024
- Management to conduct 1x1 meetings from September 9-11, 2024
- Conference held at the Lotte New York Palace Hotel
- Registration available at https://hcwevents.com/annualconference/
Pasithea Therapeutics has completed enrollment and initial dosing for the second cohort in its Phase 1 clinical trial of PAS-004, a macrocyclic MEK inhibitor aimed to treat neurofibromatosis type 1 (NF1) and other conditions. The Safety Review Committee (SRC) recommended escalating to the next dose level (4mg) after a positive safety review of the first dose cohort (2mg), which showed no dose-limiting toxicities or clinically relevant adverse events. The trial, involving patients with advanced solid tumors driven by MAPK pathway mutations, aims to assess the safety, tolerability, and pharmacokinetics (PK) of PAS-004. Initial safety and PK data are expected by Q3 2024.
Pasithea Therapeutics announced new preclinical data for PAS-004, revealing its strong inhibition of NRAS mutant cancer cell lines and superior activity in xenograft studies. PAS-004 demonstrated greater efficacy than selumetinib and binimetinib, comparable efficacy to trametinib without plateauing, and achieved over 50% maximal growth inhibition in more cell lines. The data will be presented at the ASCO Annual Meeting on June 1, 2024. PAS-004, a macrocyclic MEK inhibitor, is in clinical trials for neurofibromatosis type 1 (NF1) and other cancers, offering potential advantages in pharmacokinetics, pharmacodynamics, and tolerability.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced the acceptance of an abstract for poster presentation at the 2024 ASCO Annual Meeting for their drug PAS-004, a macrocyclic MEK inhibitor targeting neurofibromatosis type 1 (NF1) and other indications. The drug is the first of its kind in human clinical trials, offering extended half-life for improved efficacy.